We noticed JavaScript is turned off in your browser settings. For a better viewing experience, enable JavaScript. If you're unsure of how to do this, click here to download a new browser.

FOR PREVIEW ONLY (Print)

Ramachandran Murali, PhD

Director, Molecular Therapeutics Core

Associate Professor, Biomedical Sciences

Send an Email

Research Office:

Phone:

310-248-7681

Ramachandran Murali, PhD

Director, Molecular Therapeutics Core

Associate Professor, Biomedical Sciences

The research of Ramachandran Murali, PhD, focuses on the molecular basis of cancer metastasis and identification of new therapeutic strategies to limit resistance, recurrence of cancer. His studies are focused on role of the tumor necrosis factor receptors and the epidermal growth factor receptors in breast, lung and pancreatic cancers. He is working to employ structural biology for drug discovery and develop molecular probes for tumor imaging and drug delivery.

  • Doctorate: University of Madras, 1986
  • Member, American Pancreatic Association
  • Member, International Union for Crystallography
  • Ad-hoc Reviewer, CDMRP Breast Cancer (DOD)
  • Ad-hoc Reviewer, The Susan G. Komen Breast Cancer Foundation
  • Ad-hoc Reviewer, The Israel Science Foundation

Click here for a list of peer-reviewed publications.

  • Levine DH, Ghoroghchian PP, Freudenberg J, Zhang G, Therien MJ, Greene MI, Hammer DA, Murali R. Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods. 2008;46(1):25-32.
  • Murali R, Cheng X, Berezov A, Du X, Schön A, Freire E, Xu X, Chen YH, Greene MI. Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proc Natl Acad Sci U S A. 2005;102(31):10970-10975.
  • Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, Wang Q, Kao G, O'Rourke DM, Greene MI, Murali R. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol. 2000;18(2):194-198.
  • Ponde DE, Su Z, Berezov A, Zhang H, Alavi A, Greene MI, Murali R. Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. Bioorg Med Chem Lett. 2011;21(8):2550-2553.
  • Chen, CR, Hubbard PA, Salazar LM, McLachlan SM, Murali R, Rapoport B. Crystal structure of a TSH receptor monoclonal antibody: insight into Graves' disease pathogenesis. Mol Endocrinol. 2015;29(1):99-107.

Show moreShow less

Send Email to Ramachandran Murali, PhD